Shopping Cart

No products in the cart.

Heartfailure

Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.

Frailty is a severe, common co-morbidity associated with heart failure (HF) with preserved ejection fraction (HFpEF). The impact of frailty on HFpEF outcomes may affect treatment choices in HFpEF. The impact of frailty on HFpEF patients and any impact on...
🗓️ 2023-12-29
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreEfficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.

Clinical Impact of Improvement in Sarcopenia through Cardiac Rehabilitation in Patients with Heart Failure.

Sarcopenia in patients with heart failure (HF) is associated with poor prognosis. Cardiac rehabilitation (CR) decreases the incidence of adverse events in patients with HF. However, the clinical implications of improving sarcopenia status through CR remain unclear. This study investigated...
🗓️ 2024-01-03
📰 Publication: Journal Of The American Medical Directors Association
Read MoreClinical Impact of Improvement in Sarcopenia through Cardiac Rehabilitation in Patients with Heart Failure.

The burden of frailty in heart failure: Prevalence, impacts on clinical outcomes and the role of heart failure medications.

Frailty often coexists with heart failure (HF), which significantly aggravates the clinical outcomes of older adults. However, studies investigating the interplay between frailty and HF in older adults are scarce. We aimed to assess the prevalence of frailty using the...
🗓️ 2024-01-30
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreThe burden of frailty in heart failure: Prevalence, impacts on clinical outcomes and the role of heart failure medications.

Sarcopenia is linked to higher levels of B-type natriuretic peptide and its N-terminal fragment in heart failure: a systematic review and meta-analysis.

Sarcopenia is linked to impaired physical function and exercise tolerance. The aim of this systematic review and meta-analysis was to examine the association of sarcopenia and low appendicular skeletal muscle (ASM) with biomarkers of cardiac function, B-type natriuretic peptide (BNP)...
🗓️ 2024-03-08
📰 Publication: European Geriatric Medicine
Read MoreSarcopenia is linked to higher levels of B-type natriuretic peptide and its N-terminal fragment in heart failure: a systematic review and meta-analysis.

Is sarcopenia an associated factor of increased administration of specific medications in patients with heart failure? A systematic review and meta-analysis.

There is controversy in relation to commonly used drugs in heart failure (HF) and their impact on muscle function. The aim of this study was to evaluate the odds of receiving specific medications often used in clinical practice by patients...
🗓️ 2024-01-25
📰 Publication: Frontiers In Cardiovascular Medicine
Read MoreIs sarcopenia an associated factor of increased administration of specific medications in patients with heart failure? A systematic review and meta-analysis.

Increased Expression of Proinflammatory Genes in Peripheral Blood Cells Is Associated with Cardiac Cachexia in Patients with Heart Failure with Reduced Ejection Fraction.

: Cardiac cachexia (CC) in chronic heart failure with reduced ejection fraction (HFrEF) is characterized by catabolism and inflammation predicting poor prognosis. Levels of responsible transcription factors like signal transducer and activator of transcription (STAT)1, STAT3, suppressor of cytokine signaling...
🗓️ 2024-01-27
Read MoreIncreased Expression of Proinflammatory Genes in Peripheral Blood Cells Is Associated with Cardiac Cachexia in Patients with Heart Failure with Reduced Ejection Fraction.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!